Survivin is an oncogenic protein involved in cell division and acts as an anti-apoptotic factor. It is highly expressed in most cancers and is associated with chemotherapy resistance, increased tumour recurrence, and shorter patient survival. This makes anti-survivin therapy an attractive cancer treatment strategy. These functions are mediated by several survivin spliced variants, whose expression may correlate with cancer progression. One of the spliced variants, survivin-DEx3, is known to inhibit apoptosis, through undefined mechanisms. Here, we characterised these mechanisms upon TNFaÀmediated apoptosis, and showed that survivin-DEx3 acts as an adaptor, allowing the formation of a complex between Bcl-2 and activated caspase-3. The Bcl-2/survivin-DEx3 complex, but not survivin-DEx3 itself, inhibits the activity of caspase-3. Bcl-2 is therefore linked to the postmitochondrial apoptotic machinery by survivin-DEx3. Thus, survivin-DEx3 plays a key role in the inhibition of caspase-3 activity, and in the control of the mitochondrial checkpoint of apoptosis. This study suggests that targeting survivin-DEx3, rather than survivin alone, could be relevant for treating human cancers.
Survivin is an inhibitor of apoptosis, which also plays a critical role in regulating cell cycle and mitosis (Altieri, 2004) . This protein is highly expressed in most cancers and is associated with tumour cell resistance to apoptotic stimuli. This ability is essential during tumourigenesis by providing cancer cells growth advantages and conferring resistance to chemotherapy. Survivin expression is also associated with tumour recurrence and shorter survival (Altieri, 2001; Reed, 2002) .
Regulation of caspase activity is one of the mechanisms used by cancer cells to become resistant to apoptosis (Hengartner, 2000) . This function can be achieved by the cytoplasmic inhibitorof-apoptosis proteins (IAPs). IAPs contain BIR (baculovirus IAP repeat) domains, which are essential for their anti-apoptotic properties. In several cases, BIR domains directly bind to and inhibit caspase activities (Deveraux and Reed, 1999; Sun et al, 1999; Goyal, 2001) . Caspase activities are also regulated by another anti-apoptotic family: the Bcl-2 family (Frade and Michaelidis, 1997) . In mammalian cells, several adaptor proteins, bridge caspases to Bcl-2 or Bcl-xL, to control their activation (Ng et al, 1997; Chau et al, 2000; Zhang et al, 2003) . Such adaptors link the mitochondrial Bcl-2 family members to the postmitochondrial apoptotic machinery, and thereby play an important role in the regulation of apoptosis.
Survivin was originally identified by its structural homology to the IAP family of proteins in human B-cell lymphoma (Ambrosini et al, 1997) . In human cells, there are four spliced variants of survivin: survivin-2B; survivin-2a, survivin-3B, and survivin-DEx3. Their expression levels correlate with cancer progression (Li, 2005) . Survivin-DEx3 is generated by the removal of exon 3 (Mahotka et al, 1999; Badran et al, 2004; Caldas et al, 2005) . The open reading frame of survivin-DEx3 encodes a protein with an interrupted BIR domain and a unique 63 amino-acid long Cterminal tail (Mahotka et al, 1999) . Overexpression of survivinDEx3 is observed in several human malignancies, including renal cell carcinoma, breast cancer, gastric carcinoma, and medulloblastoma (Krieg et al, 2002; Mahotka et al, 2002a; Fangusaro et al, 2005; Ryan et al, 2005) . In addition, expression of survivin and survivin-DEx3 remains constant in different stages of cancer (Krieg et al, 2002) . Patients with soft-tissue sarcoma also have an increased risk of tumour-related death when survivin-DEx3 is overexpressed (Taubert et al, 2005) . The expression level of survivin-DEx3 is inversely correlated with apoptotic index in gastric cancers (Meng et al, 2004) .
Survivin-DEx3 inhibits apoptosis, through undefined mechanisms (Mahotka et al, 1999 (Mahotka et al, , 2002a . The protein has a unique Cterminus, and novel anti-apoptotic features could be mediated by this region. We previously suggested that a mitochondrial targeting signal (MTS) and a putative BH2 domain may be located in this region (Wang et al, 2002) . Survivin-DEx3 preferentially localises in the nucleus during late G1 to G2 phases of the cell cycle (Fortugno et al, 2002) . A nuclear localisation signal (NLS) is embedded in its unique C terminus (Mahotka et al, 2002b) . Survivin-DEx3 is also distributed in the cytosol, with a fraction located at the mitochondria in HeLa and Daoy cells (Rodriguez et al, 2002; Mahotka et al, 2002b; Caldas et al, 2005; You et al, 2006) . Survivin and survivin-DEx3 form heterodimers, thereby regulating the balance between proliferation and cell death . Other binding partners may additionally contribute to the anti-apoptotic function of survivin-DEx3.
Previously, we showed that a viral protein vIAP (viral inhibitorof-apoptosis protein), which is encoded by ORF K7 of human Kaposi's sarcoma-associated herpesvirus (KSHV), is an adaptor between Bcl-2 and activated caspase-3, thereby, enabling Bcl-2 to inhibit caspase-3 activity (Wang et al, 2002) . We found that vIAP is structurally and functionally related to survivin-DEx3: both proteins contain a disrupted BIR domain, an MTS, and a putative BH2 domain (Wang et al, 2002) . However, it is not yet clear, whether survivin-DEx3 also achieves its anti-apoptotic function in a similar way to that of vIAP. We hypothesised that survivin-DEx3 may achieve its anti-apoptotic function by bridging mitochondrial proteins, such as Bcl-2, to caspases.
Here, we showed that upon TNFa treatment, survivin-DEx3 localises at the mitochondria, where it binds to Bcl-2 and to activated caspase-3, acting as an adaptor, which allows Bcl-2 to inhibit the activity of caspase-3. Thus, this study suggests that survivin-DEx3 is a central regulator at the mitochondrial checkpoint during TNFa-induced apoptosis.
MATERIALS AND METHODS

Plasmids
pCR3.1-survivin and pCR3.1-survivin-DEx3 expressing haemagglutinin-tagged forms were described previously (Wang et al, 2002) . pCR3.1-survivin-DEx3(DBIR) (deleted aa 38 -43) and pCR3.1-survivin-DEx3(DBH2) (deleted aa 101 -107) were created using the QuickChange mutagenesis kit (Stratagene, Amsterdam, The Netherlands) to introduce deletion mutations in pCR3.1-survivin-DEx3. pGST-survivin-DEx3(118), pGST-survivin-DEx3(100), pGST-survivin-DEx3(70), and pGST-survivin-DEx3(CT) were created by PCR amplification from pCR3.1-survivin-DEx3, and then cloned in pGEX6P1 vector (Amersham Pharmacia Biotech, Bucks, UK).
RNA interference
Targets for RNA interference were selected using the Dharmacon sequence selection tool (www.dharmacon.com). First, we attempted to develop a survivin-DEx3-specific siRNA. Since survivin contains all the sequences that survivin-DEx3 has, we designed siRNA using the only specific sequences of survivin-DEx3 at the junction of exons 2 and 4, but we did not obtain any knock-down effect. In consequence, a global approach to knock-down survivinDEx3 was used. DNA oligos containing the target sequence, a TTCG hairpin, the antisense of the target, a five T termination sequence, and a CTAG (XbaI site) were synthesised by (MWG Biotech, London, UK), annealed and inserted into the pGEM-U6M plasmid by digestion with XbaI and SmaI (Promega, Southampton, UK) and ligated with T4 DNA ligase (NEB, Herts, UK). pGEM-U6M was created from pGEM-U6L and altering the þ 1 base pair of the U6 promoter from G to C using the Stratagene quickchange site directed mutagenesis kit. Lentiviral RNA interference plasmids were then generated by subcloning the U6 promoter-hairpin construct from pGEM-U6M into pCSGW by digestion with EcoRI. The short hairpin targeting all three survivin isoforms is ggaccaccgcatctctacattc.
Glutathione S-transferase (GST) pull-down, immunoprecipitation, Western blot, and immunofluorescence microscopy
The expression of recombinant glutathione S-transferase (GST) fusion proteins, GST pull-down assays, in vivo co-immunoprecipitations, and Western blots were described previously (Wang et al, 2002) . The following primary antibodies were used: antisurvivin (6E4 mAb, Cell Signaling, Danvers, USA), anti-HA (BabCo, Cambridge, MA, USA), anti-cytochrome c (Upstate, Chandlers Ford, UK), anti-Bcl-2 (BD Pharmingen, Oxford, UK), anti-caspase-3 (BD Pharmingen). Transfections were performed using fuGENE6 transfection reagent (Roche, Welwyn Garden City, UK). For immunofluorescent assay (IFA), HeLa cells were fixed and permeabilised using formalin 3.7% and PBS-T-0.1% Triton X-100, as previously described (Wang et al, 2002) . Images were taken using a confocal microscope (Leica TSC Systems, Bucks, UK).
Subcellular fractionations
A method described previously (Wang et al, 2002) was used to divide cells into intact nucleus, intact mitochondria, and cytosol fractions
RNA extraction and RT -PCR
RNA extraction and RT -PCR were performed, as previously described (Wang et al, 2002) . The sense primer for specific amplification of survivin-DEx3 cDNA is as follows: 5 0 -GACG ACCCCATGCAAAGGAAAC-3 0 , and the antisense primer is the same as that used for survivin-DEx3/survivin cloning.
Comparative protein modelling and bioinformatics tools
The MODELLER program (http://salilab.org/modeller/modeller.html) was applied in the comparative modelling work (Sanchez and Sali, 2000) . Protein templates used in comparative modelling were downloaded from the PDB database (http://www.rcsb.org/ pdb/index.html). The RasMol software (www.umass.edu) and the Swiss-PdbViewer program (v3.7) (www.expasy.org/spdbv) were used to view and analyse the resulting models. To further characterise the intracellular localisation of different proteins, we used the TMprep program (www.ch.embnet.org/software/ TMPRED_form.html), which makes a prediction of membranespanning regions and their orientation based on the statistical analysis of the TMbase database (www.ch.embnet.org/software/ tmbase/TMBASE_doc.html). Another independent algorithm, the TopPrep program (bioweb.pasteur.fr/seqanal/interfaces/toppred.html), is also used to confirm the reliability of the TMprep program.
Induction of apoptosis, apoptotic assays, and flow cytometry analyses
For TNFa-induced apoptosis, transfected HeLa cells were cultured in the presence of 10 ng ml À1 of TNFa (Sigma, Gillingham, UK) plus 1 mg ml À1 of cycloheximide (Sigma) for the indicated time period. For Bax-induced apoptosis, 4 Â 10 5 of cells were transfected with Bax-expression plasmids and incubated at 371C for 48 h or 24 h. To measure mitochondrial transmembrane potential (DCm), 5 Â 10 5 of transfected cells were incubated with 500 mM of CMXRosamine (Molecular Probes, Paisley, UK) at 371C for 30 min. To evaluate cell viability, cells were resuspended in propidium iodide (PI) solution (2 mg ml À1 PI in PBS with 1% BSA and 0.01% azide, BD Pharmingen, UK) at 201C for 20 min. Treated cells were washed in PBS, then analysed for fluorescence using FACSCaliburt flow cytometry with the CellQuest software (Becton Dickinson, Franklin Lakes, NJ, USA). A total of 20 000 cells were counted in each experiment, and the numbers reported represent the average and standard deviation (s.d.) of at least three independent experiments. For the caspase-3 activity assays, we used the ApoAlert caspase-3 fluorescent assay kit (Clontech, SaintGermain-en-Laye, France).
RESULTS
Expression of survivin-DEx3 in human cancer and normal cell lines
The domain organisation of survivin, survivin-2B, survivin-DEx3, and vIAP is represented in Figure 1A . We investigated the transcriptional expression of survivin and survivin-DEx3 in several human cancer and normal cell lines. The mRNA of survivin-DEx3 is detected by semiquantitative RT -PCR in cell lines derived from human cancers, like for Kaposi sarcoma (lanes 2, 3), cervival carcinoma (lane 4), fibrosarcoma (lane 5), non-small lung carcinoma (lane 7), osteosarcoma (lanes 8 -9), leukaemia (lane 13), and also from cell lines established from normal tissues, like embryonic kidney cells (lane 1), pulmonary epithelial cells (lane 6), endothelial cells from umbilical vein (lanes 10, 11). All the cell lines tested were positive for survivin-DEx3 ( Figure 1B ). Expression of both survivin and survivin-DEx3 transcripts has also been detected in human primary cells ( Figure 1C ). Survivin-DEx3, like survivin (Adida et al, 1998) , is detectable in fetal tissues, suggesting that this protein may be another oncofetal protein deregulated in cancers.
Localisation of survivin-DEx3 and vIAP
We next analysed the sequence of survivin, survivin-DEx3, and vIAP, using computational protein modelling tools. Two different computational analyses suggested a putative localisation to the membrane of survivin-DEx3, with inside-out orientation of the C-terminus domain ( Figure 1D ).
We next characterised the localisation of survivin-DEx3 and vIAP using IFA in survivin-DEx3-or vIAP-expressing HeLa cells, stained with a mitochondria-specific dye ( Figure 1E ). Consistent with previous reports You et al, 2006) , survivin-DEx3 and vIAP are localised in the nucleus, the cytosol, and particularly in the mitochondria ( Figure 1E ). Using subcellular fractionation assays, we showed that both proteins can be found in the mitochondrial fraction in HeLa cells. The mitochondrial distribution pattern of survivin-DEx3 and vIAP was similar to that of Bcl-2, but distinct from that of survivin ( Figure 1F ), which is known to reside in the cytoplasm and to translocate into the nucleus during mitosis (Fortugno et al, 2002) .
Survivin-DEx3 protects cells from apoptosis
We tested if survivin-DEx3 shares with vIAP its ability to protect cells from apoptosis, upon different apoptotic treatments. We investigated the mitochondrial function of survivin-DEx3, and showed that the expression of survivin-DEx3 prevents cytochrome c release in 293 cells upon Bax-induced apoptosis ( Figure 3C ) and protects HeLa cells from TNFa-induced apoptosis ( Figure 1G ). The ability of survivin-DEx3 to protect cells from apoptosis was comparable to that of KSHV vIAP, survivin, and Bcl-2. It was reported that the diverse functions of survivin may be explained partly by its ability to heterodimerise with its splicing variants in tumour cells . Survivin and survivin-DEx3 interact at the mitochondria, where they may protect cells from mitochondrial-dependent apoptosis . Using a GST pull-down, we further showed that both vIAP and survivinDEx3 could heterodimerise with survivin, via the BIR domain ( Figure 1H ).
Survivin-DEx3 associates with both Bcl-2 and activated caspase-3
Next, we investigated the mechanisms by which survivin-DEx3 inhibits TNFa-mediated apoptosis. Certain mammalian IAPs and the KSHV vIAP are able to bind directly to caspases, via their BIR domains (Deveraux and Reed, 1999; Goyal, 2001; Wang et al, 2002) . We therefore investigated whether the disrupted BIR domain of survivin-DEx3 could still bind to the active form of caspase-3. To gain further insights into the interaction between activated caspase-3 and survivin-DEx3, we computationally modelled the putative survivin-DEx3 -caspase-3 complex. According to the published structure of the XIAP BIR2-caspase-3 complex (PDB ID: 1I3O (Riedl et al, 2001) , Figure 2A , lower panel), the topological contact between survivin-DEx3 and active caspase-3 is predicted to be through the globular BIR domain of survivin-DEx3 with the edge, but not with the catalytic pocket of the enzyme caspase-3 (Figure 2A, upper panel) . In contrast, it is reported that XIAP can further bind to the substrate-binding cleft of active caspase-3, via its N-terminal linker, hence, providing a steric blockade mechanism for substrate binding (Figure 2A , lower panel). This computational model implied that although survivinDEx3 could bind to active caspase-3, this interaction may not be sufficient for survivin-DEx3 to inhibit the activity of this enzyme. Other cofactors may be required for the anti-apoptotic function of survivin-DEx3.
We tested if survivin-DEx3 can interact directly with activated caspase-3. Four different deletion mutants of survivin-DEx3 were designed and cloned in fusion with recombinant GST to map the different domains within survivin-DEx3 potentially involved in the interaction with caspase-3 ( Figure 2B , upper panel), and a GST pull-down assay was performed. We showed that recombinant active caspase-3 is pulled down by survivin-DEx3 and that only the interrupted BIR domain is necessary and sufficient for this interaction ( Figure 2B, lanes 1 and 4) . These interactions were specific, as GST only, or the C-terminus of survivin-DEx3, which does not contain BIR domain did not pull down active caspase-3 ( Figure 2B , lanes GST and 2).
We have previously shown that the KSHV vIAP suppresses caspase-3 activity, only when it also binds to Bcl-2 (Wang et al, 2002) . It is possible that survivin-DEx3 also inhibits indirectly caspase-3 activity, by also binding to Bcl-2. We therefore tested survivin-DEx3 and Bcl-2 interaction by in vivo co-immunoprecipitation (IP) in HeLa cell extracts expressing vIAP, survivin-DEx3, and survivin-DEx3(DBH2) with an anti-Bcl-2 mAb. We showed that survivin-DEx3 and vIAP (used here as a positive control), but not the BH2 domain-deleted survivin-DEx3 mutant, were immunoprecipitated with endogenous Bcl-2 ( Figure 2C ). This experiment showed that survivin-DEx3 binds to Bcl-2 via its BH2 domain.
To test the interaction between Bcl-2 and activated caspase-3, an in vivo Bcl-2 IP was performed in a TNFa-treated HeLa cell lysate expressing endogenous survivin-DEx3. The active form of caspase-3 was immunoprecipitated with Bcl2, validating the existence of a tripartite complex between survivin-DEx3, Bcl-2, and active caspase-3 ( Figure 2D ).
The ability of survivin-DEx3 to mediate the interaction between caspase-3 and Bcl-2 was tested by knocking down endogenous survivin-DEx3. Short hairpin RNAs expressed by a lentiviral vector were used to eliminate the expression of all endogenous survivin isoforms, and an in vivo Bcl2 IP was performed on survivin-DEx3 positive-and negative-HeLa cell lysates. Activated caspase-3 could be immunoprecipitated in complex with Bcl-2, only when survivin-DEx3 is present ( Figure 2E ). The absence of caspase-3 on Bcl-2 IP when all isoforms of survivin are knocked down is likely to be due to the absence of survivin-DEx3, rather than survivin, as survivin does not interact with Bcl-2 (Supplementary Figure B ).
Survivin-DEx3 associates with Bcl-2 to inhibit the function of activated caspase-3
The functional significance of the association between survivinDEx3, Bcl-2, and active caspase-3 was further addressed by testing the ability of survivin-DEx3 and several mutants to inhibit endogenous caspase-3 activity upon TNFa-induced apoptosis, using a caspase fluorescent substrate assay. We found that survivin-DEx3, like vIAP (Wang et al, 2002) , inhibits caspase-3 activity. Such inhibition required the presence of a functional BH2 domain (necessary for binding to Bcl-2) and also a functional BIR domain (necessary for binding to caspase-3; Figure 3A ). Using recombinant caspase-3 also showed that both BH2 and BIR domains are required (Supplementary Figure A) . Overall, these data indicate that survivin-DEx3 protects cells from TNFa-induced apoptosis, by acting through a caspase-3-dependent pathway.
Finally, we investigated whether the ability of survivin-DEx3 to associate to Bcl-2 and caspase-3 is essential for its anti-apoptotic function. The BH2 and BIR domains of survivin-DEx3 were deleted, and we monitored for each mutant their aptitude to protect cells by measuring the loss of mitochondrial membrane potential (Dcm), using a dye specific for intact mitochondrial membranes ( Figure 3B ). Survivin-DEx3 protects HeLa cells from TNFa-induced apoptosis as much as vIAP, used here as a positive ) plus cycloheximide (1 mg ml
À1
) for 2 h. Immunoprecipitations were performed as previously, and were analysed with anti-active caspase-3 antibody. (E) Survivin-DEx3 is an essential bridge between Bcl-2 and active caspase-3. HeLa cells were pre-infected with either empty lentivirus (V) or lentivirus stably expressing RNAi against all isoforms of survivin (KO). Apoptosis and immunoprecipitation were performed as described previously.
control ( Figure 3B ). The deletion of the BH2 or of the BIR domains resulted in a significant reduction of the anti-apoptotic activity of survivin-DEx3 ( Figure 3B ).
We also monitored the translocation of cytochrome c from mitochondria into the cytosol, as a marker for mitochondrial integrity, upon Bax-induced apoptosis in 293T cells. SurvivinDEx3 prevented cytochrome c translocation, while the two mutants did not ( Figure 3C ). The different protective effects of survivinDEx3 mutants cannot be attributed to variations in protein expression level, since all mutants were expressed similarly (Figure 3 , Western blot), and all survivin-DEx3 remained localised at the mitochondria. Overall, these data suggest that binding to active caspase-3 alone or Bcl-2 alone is not sufficient for survivinDEx3 to inhibit the enzymatic activity of caspase-3. To achieve a complete anti-apoptotic function, survivin-DEx3 requires an association with both partners (Figure 3) . 
DISCUSSION
We have shown that survivin-DEx3 shares a number of similarities with vIAP ( Figure 1 ; Wang et al, 2002) , such as their localisation to the mitochondrial compartment, their ability to heterodimerise with survivin, and their anti-apoptotic activity upon TNFa treatment. One of the anti-apoptotic mechanisms of survivinDEx3 is mediated by its association with both Bcl-2 and active caspase-3, in order to inhibit the activity of the bound enzyme (Figures 2 and 3) . These data confirm our hypothesis that survivinDEx3 is an anti-apoptotic factor, functioning like vIAP (Wang et al, 2002) . It is known that survivin-DEx3 is overexpressed in a number of tumours, and may contribute to tumourigenesis by protecting malignant cells from apoptosis by undefined mechanisms (Mahotka et al, 1999 (Mahotka et al, , 2002a (Mahotka et al, , 2002b . Our data provide further insights into these mechanisms. Survivin-DEx3, like survivin, protects cells from methotrexate, lymphotoxin-b receptor, and CD95-induced apoptosis (You et al, 2006) . Here, we showed that survivin-DEx3 also protects cell from TNFa-induced apoptosis, defining survivin-DEx3 as a key factor of the mitochondrial checkpoint of apoptosis.
In mammals, several adaptor proteins bridge caspases to Bcl-2 or Bcl-xL to prevent their activation. For example, Bap31 contributes to the regulation of procaspase-8, and this activity is dependent on the presence of Bcl-2 or Bcl-xL within the same complex (Ambrosini et al, 1997) . A novel BH3-only protein, Spike, inhibits the formation of a complex between Bap31 and Bcl-xL, thereby favouring apoptosis (Mund et al, 2003) . We previously showed that vIAP functions as an adaptor linking Bcl-2 to activated caspase-3, and thereby controlling its activity (Wang et al, 2002) . Here, we showed that one of the anti-apoptotic mechanisms of survivin-DEx3 is also to act as an adaptor, linking Bcl-2 to active caspase-3, through its BH2 and BIR domains, respectively. This enables Bcl-2 to inhibit the activity of caspase-3 and to protect cells from apoptosis. Using a knock-down approach, we have demonstrated that survivin-DEx3 is essential to link Bcl-2 to caspase-3. Indeed, without any survivin-DEx3 expression detectable, we significantly reduced the quantity of caspase-3 interacting with Bcl-2 ( Figure 2E ). Survivin-DEx3 provides a link between two major apoptotic pathways. Our data were obtained in the context of TNFa-induced apoptosis, which is one of the main pathways involved in the control of cell survival -apoptosis balance.
We also studied the role of survivin-DEx3 upon Bax-induced apoptosis, which is part of the TNFa-induced responses. We showed that survivin-DEx3 is able to maintain the mitochondrial transmembrane potential and to prevent the translocation of cytochrome c from mitochondria ( Figure 3C ). This concurs with recent data showing that overexpression of survivin-DEx3 prevents LTbRinduced release of cytochrome c and Smac/DIABLO. LTbR is a member of another TNF superfamily group, which is specifically involved in developmental programmes (You et al, 2006) . Some members of the IAP family are E3 ubiquitin ligases (Vaux and Silke, 2005) , involved in substrate ubiquitination and degradation by the 26S proteasome. For example, XIAP and livin protect cells from TRAIL-induced apoptosis by targeting proapoptotic molecules, such as Smac/DIABLO, for proteasomal degradation (MacFarlane et al, 2002; Ma et al, 2006) . It remains to be investigated whether survivin-DEx3 holds ubiquitin-ligase activity, or interacts with an E3 ligase to protect cells from mitochondrial damage by targeting pro-apoptotic molecules for proteasomal degradation. In TNFa-induced responses, caspaseindependent signalling pathways are also involved. We showed here that survivin-DEx3, upon TNFa-induced cell death, prevents the activation of caspase-3. As some IAPs regulate apoptosis by interacting with various components of the MAPK family (Zhang et al, 2003; You et al, 2006) , survivin-DEx3 may also be able to play a role via caspase-independent pathways.
We have also shown that survivin-DEx3 is able to heterodimerise with survivin. This suggests that the splice variants of survivin contribute to regulate the balance between proliferation and cell death. As survivin links cell proliferation, survival, and stress responses, studies targeting survivin are being exploited, using diverse approaches from immunotherapy to small molecule antagonists (Altieri, 2006) . Targeting survivin-DEx3, rather than survivin alone, may selectively and effectively destroy tumour cells, by suppressing their ability to resist apoptosis. Overall, these findings suggest that survivin-DEx3 is a potential target for future anti-cancer therapies.
Supplementary Information accompanies the paper on British Journal of Cancer website (http://www.nature.com/bjc)
